Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma

• 主要な著者: Rene John D. Febro (著者), Engelbert Simon S. Perillo (著者), Akemi A. Kimura (著者), Stephen N. Wong (著者)
• フォーマット: 図書
• 出版事項: Korean Liver Cancer Association, 2024-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Backgrounds/Aims Atezolizumab/bevacizumab is the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) and may facilitate curative conversion through resection and locoregional therapies. However, there have been very few reports on curative conversion using microw...